In a CCL4-induced rat liver fibrosis model [808], BM-MSCs treatment reduced IL-17, IL-2 and IL-6 serum proteins and downregulated IL-17A and IL-17RA proteins in liver tissues [530]. Here, IL17A is linked to Hepatic fibrosis.